Pharma companies fiercely compete to develop ADC drugs

By Son, Hyung-Min | translator Kim, Jung-Ju

23.11.29 06:00:42

가나다라 0

Many Korean biopharmaceutical companies participate in ADC developments

Is searching for candidate substances in the form of an open innovation due to its high difficulty in development

Competition among domestic pharmaceutical companies to secure new antibody-drug conjugate (ADC) technology has been intensifying in Korea. With ADC drugs recently demonstrating an effect on various cancer types, there is an analysis that the industry is making active measures to secure new ADC technologies.

According to the pharmaceutical industry on the 29th, not only pharmaceutical companies such as Samjin Pharm and Chong Kun Dang, but also bio companies such as LegoChem Biosciences, ABL Bio, PinotBio, AIMed Bio, Celltrion, Samsung Biologics, and Lotte BioLogics have entered the ADC market.

ADCs are drugs made by connecting antibodies that bind to specific target antigens on the surfac

Son, Hyung-Min(shm@dailypharm.com)

If you want to see the full article, please JOIN US (click)